JOUNCE THERAPEUTICS INC (JNCE)
US4811161011 - Common Stock
| 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | 2018 (2018-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 150.57M | 95.53M | 147.50M | 53.20M | 47.90M | |||
| Marketable Securities | 38.97M | 83.04M | 59.00M | 115.60M | 142.00M | |||
| Receivables | N/A | N/A | N/A | N/A | 400.00K | |||
| Other Current Assets | 7.69M | 12.26M | 4.90M | 4.90M | 1.90M | |||
| Total Current Assets | 197.23M | 190.83M | 211.40M | 173.70M | 192.20M | |||
| Non-Current Assets | ||||||||
| PPE Net | 12.32M | 16.76M | 22.20M | 28.30M | 13.50M | |||
| Investments And Advances | 0.00 | 41.66M | 6.70M | 1.60M | 6.00M | |||
| Other Non-Current Assets | 3.00M | 3.45M | 3.90M | 2.30M | 2.70M | |||
| Total Non-Current Assets | 15.32M | 61.87M | 32.80M | 32.20M | 22.30M | |||
| TOTAL ASSETS | 212.55M | 252.70M | 244.20M | 205.90M | 214.50M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Accrued Expenses | 21.30M | 17.16M | 15.30M | 11.80M | 7.00M | |||
| Accounts Payable | 2.10M | 1.67M | 2.00M | 2.50M | 3.30M | |||
| Other Current Liabilities | 178.00K | 62.00K | 2.00M | 100.00K | 55.30M | |||
| Total Current Liabilities | 23.57M | 18.90M | 19.30M | 14.40M | 65.50M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Other Non-Current Liabilities | 5.87M | 9.99M | 13.60M | 16.90M | 44.80M | |||
| Total Non-Current Liabilities | 5.87M | 9.99M | 13.60M | 16.90M | 44.80M | |||
| TOTAL LIABILITIES | 29.44M | 28.89M | 32.90M | 31.30M | 110.30M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -292.79M | -241.87M | -151.00M | -107.20M | -163.90M | |||
| Additional Paid In Capital | 476.53M | 465.87M | 362.30M | 281.70M | 268.10M | |||
| Common Shares | 51.00K | 51.00K | 0.00 | 0.00 | 0.00 | |||
| Other Shareholders' Equity | -677.00K | -238.00K | 0.00 | 100.00K | -100.00K | |||
| Shares Outstanding | 51.69M | 51.27M | 41.70M | 33.70M | 32.90M | |||
| Tangible Book Value per Share | 3.54 | 4.37 | 5.07 | 5.18 | 3.16 | |||
| Total Shareholders' Equity | 183.11M | 223.81M | 211.30M | 174.60M | 104.10M | |||
| TOTAL LIABILITIES AND EQUITY | 212.55M | 252.70M | 244.20M | 205.90M | 214.50M | |||
| Statistics | ||||||||
| Debt/Equity | N/A | N/A | N/A | N/A | N/A | |||
| Current Ratio | 8.37 | 10.10 | 10.95 | 12.06 | 2.93 | |||
| Return On Assets (ROA) | -23.96% | -35.96% | -17.94% | 27.59% | -12.77% | |||
| Return On Equity (ROE) | -27.81% | -40.60% | -20.73% | 32.53% | -26.32% | |||
| Return On Invested Capital (ROIC) | N/A | N/A | N/A | 21.78% | N/A | |||
| Return On Invested Capital Ex Cash (ROICexc) | N/A | N/A | N/A | 183.75% | N/A | |||
| Return On Invested Capital Ex Cash + Goodwill (ROICexcg) | N/A | N/A | N/A | 183.75% | N/A | |||
All data in USD